Summary sheet
This project will support Bavarian Nordic, a fully integrated Danish biotechnology company focused on the development, manufacturing and commercialisation of cancer immunotherapies and vaccines for infectious diseases. Financing is required for capital expenditure investments in Denmark.
The project supports the company's investments into a new fill-finish manufacturing facility. The investments cover the operational expenditure (OPEX) and capital expenditure (CAPEX) costs to construct, furnish and validate the new manufacturing facility to a commercial level. By co-investing in this project, the Bank contributes to fostering the generation of scientific knowledge and acumen within Europe, in addition to creating skilled employment opportunities.
The project falls under the annex II of the Environmental Impact Assessment (EIA) directive (2014/52/EU), referring to the manufacture of pharmaceutical products. The project has been screened by the competent authorities and there is no EIA required. Full environmental details will be assessed during the appraisal.
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
Documents
News & Stories
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications